Information Provided By: 
Fly News Breaks for May 13, 2019
HOOK
May 13, 2019 | 07:03 EDT
RBC Capital analyst Brian Abrahams initiated Hookipa Pharma with an Outperform rating and a price target of $23. The analyst believes that the vaccines from the company's arenavirus platform could yield an "optimal immune upregulation" in the treatment and prevention of infectious diseases, and expects these to "drive considerable long-term value as they mature." Abrahams also cites the platform's "validation" in Hookipa's partnership with Gilead that should lead to "monetization" of the company's technology.
News For HOOK From the Last 2 Days
There are no results for your query HOOK
